Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country

Yeh Chunn Kuan, Soon Hin How, Abdul Aziz Azian1, Chong Kin Liam2, Teck Han Ng, Abdul Rani Fauzi

Abstract:

INTRODUCTION: Prolonged use of oral corticosteroids is a risk factor for osteoporosis. However, the effect of inhaled corticosteroids (ICS) on bone mineral density (BMD) of asthmatic patients remains controversial.

OBJECTIVES: We aimed to determine the prevalence of osteopenia and osteoporosis in our patients with asthma receiving ICSs for more than one year compared with patients who did not have asthma and to determine the risk factors for osteopoenia and osteoporosis among the asthmatic patients.

METHODS: This was a cross-sectional study conducted from August 2007 to July 2009. Asthmatic patients aged 18 years and older who had been on ICS for at least one year and a control group of subjects not on ICS were included. BMD was measured using DEXA (dual energy X-ray absorptiometry) scan. The WHO classification of T-scores for osteopenia and osteoporosis were used.

RESULTS: A total of 143 subjects were recruited (69 asthmatics and 74 control subjects). T-scores of the spine, femur, and hip showed significant negative correlation with age and significant positive correlation with body mass index (BMI).

CONCLUSION: The risk factors for osteoporosis and osteopenia among asthmatic patients were older age and lower BMI, but not the cumulative dose of ICS. Asthmatic patients on ICS have no added risk of osteoporosis or osteopenia as compared with non-asthmatic subjects.

Key words: Asthma, asthma, bone mineral density, inhaled corticosteroids

The prevalence of asthma in Malaysia is 4.1% among adults, as reported in the Second National Health and Morbidity Survey conducted by the Ministry of Health of Malaysia. According to this report, 19.4% of adult asthmatics were on inhaled corticosteroids (ICS). ICSs are the recommended therapy for chronic persistent asthma in both the Malaysian and international guidelines. However, there is no recommendation on whether asthmatic patients should be screened or treated for osteoporosis. The use of oral glucocorticoid equivalent of >5 mg prednisolone daily for >3 months is a strong risk factor for reduced bone mineral density (BMD). On the other hand, evidence for the effects of ICS on BMD has been conflicting.

Several short-term prospective studies of less than two years have suggested that ICS reduce bone formation as demonstrated by lowered osteocalcin level, but not all have concluded that BMD was significantly different compared with control subjects. As a matter of fact, one study actually showed that larger cumulative ICS doses were associated with higher BMDs and a reduction in the number of patients at risk of fracture. A large proportion of the patients with moderate to severe asthma treated in our hospital are on long-term moderate-to-high doses of ICS and they usually require rescue courses of oral corticosteroids during exacerbations. We aimed to determine the prevalence of osteopenia and osteoporosis in our patients with asthma receiving ICS for more than one year compared with subjects who did not have asthma and to determine the risk factors for osteopenia and osteoporosis among our asthmatic patients.

Methods

This study was conducted in Hospital Tengku Ampuan Afzan in Kuantan, Malaysia. The hospital is an 800-bed tertiary referral center for medical and surgical disciplines. The emergency department of the hospital provides acute asthmatic care to patients and the specialist respiratory clinic sees 40 asthmatic patients per month. The standard course of oral prednisolone given for acute exacerbations is 30 mg daily for five days.

This is a cross-sectional study conducted over the
period of August 2007 to July 2009. Consecutive adult asthmatic patients aged 18 years or older who attended the asthma clinic of our hospital and who had been on ICS continuously for at least the past one year were included after obtaining written informed consent. They were compared with a control group of adults who were not on ICS, recruited from non-respiratory medical outpatient clinics. Control subjects also fulfilled all inclusion and exclusion criteria but they were not receiving ICS. Patients who had known factors affecting BMD which included calcium supplement consumption and hormone replacement therapy were excluded from the study. Also excluded were current smokers and ex-smokers who smoked more than 100 cigarettes in the past, i.e., ever smokers who smoked less than 100 cigarettes in their lifetime are allowed to participate in the study. Regarding alcohol consumption, male subjects who consumed >21 units/week and female subjects >14 units/week were classified as “significant alcohol consumption.” The asthmatic patients were interviewed regarding the severity of the disease and details of treatment based on historical recall which included the dose and the type of ICS and average number of rescue courses of oral corticosteroids per year.

BMD of each subject was assessed using dual energy X-ray absorptiometry (DEXA) which was performed by the radiographer using a whole-body bone densitometer (Hologic Discovery W, Bedford, USA). T-score was used to define osteopenia (−2.5<T-score<−1.0) and osteoporosis (T-score<−2.5) based on the WHO classification. Control of asthma was assessed according to the GINA guidelines[3] which classified the patients’ asthma as controlled, partly controlled, or uncontrolled.

Statistical analysis
All ICS received by patients were converted into budesonide equipotent doses for data analysis. Physical activity was measured using the physical activity index[12] (PAI). PAI is the sum of the number of hours spent for each activity on an average day multiplied by the activity’s weight factor, which is determined by the intensity level of the activity.

Results are expressed as mean±SD or median (interquartile range [IQR]). The data were analyzed using Statistical Package for the Social Sciences (SPSS) version 12.0 (Chicago, USA). Statistical significance was taken at P<0.05. Categorical variables and parametric and non-parametric continuous variables were analyzed using Chi-square, Student t-test, and Mann-Whitney statistical tests depending on their normality. Tests for correlation between T-scores and age, body mass index (BMI), and PAI were also performed. Factors affecting variables were analyzed using Chi-square, Student P—test, and correlation and significant positive correlation between age and BMI, respectively, and the T-scores of the spine, hip, and femur [Table 4]. Among female asthmatic patients, osteoporosis and osteopenia were present in 11.7% and 48.3%

Results
A total of 143 subjects were recruited. Sixty-nine patients were asthmatics and were on ICSs for the past one year and the rest were control subjects. The ICSs used comprised of budesonide, fluticasone, and beclomethasone. The mean daily budesonide equipotent dose was 673±206 µg/day (range, 200 to 1200 µg/day). The majority of the patients and control subjects were females and the characteristics of both groups are shown in Table 1. There were no statistical significant differences between the two groups, except that the control subjects had more physical activity compared with the asthmatics.

From the DEXA scan results, there were no differences in the T-scores of the hip, femur, and spine between the asthmatics and the control group [Table 2]. More control subjects than asthmatic patients had osteopenia or osteoporosis [Figure 1], although this difference was not statistically significant (51.4% vs 43.4%, P=0.592).

Overall, 10 (7.0%) asthmatic patients had osteoporosis, 58 (40.6%) patients had osteopenia, and the remaining had normal BMD. There were no significant difference in terms of gender, smoking status, alcohol consumption, and family history of osteoporosis/osteopenia between patients with osteoporosis/osteopenia and those with normal BMD [Table 3]. Among the asthmatic patients, there was significant negative correlation and significant positive correlation between age and BMI, respectively, and the T-scores of the spine, hip, and femur [Table 4]. Among female asthmatic patients, osteoporosis and osteopenia were present in 11.7% and 48.3%

Table 1: Characteristics of asthmatic patients and control patients

| Characteristic          | Asthmatic patients (n=69) No. (%) | Control patients (n=74) No. (%) | P value |
|------------------------|----------------------------------|--------------------------------|---------|
| Male: Female           | 12:57                            | 8:66                           | 0.257   |
| Age (year)             | 52 IQR: 15                       | 52 IQR: 10                     | 0.187   |
| Body mass index (BMI)  | 27.5±5.4                         | 25.0±5.1                       | 0.331   |
| PAI                    | 27.7 IQR: 3.2                    | 28.9 IQR: 1.9                  | 0.028   |
| No. of ever-smokers    | 4 (5.8)                          | 1 (1.4)                        | 0.162   |
| No. of subjects with “significant alcohol consumption” | 2 (2.9) | 4 (5.4) | 0.455 |
| No. of postmenopausal women | 24 (41) | 36 (54) | 0.228 |
| No. with family history of osteoporosis | 2 (2.9) | 6 (8.1) | 0.176 |

IQR = Interquartile range

Table 2: Mean or median T-score among asthmatic patients and control subjects

| Site       | Asthmatic patients (n=69) | Control subjects (n=74) | P value |
|------------|----------------------------|-------------------------|---------|
| Spine      | −0.72 ± 1.30               | −0.57 ± 1.29            | 0.980   |
| Femur      | −0.60 IQR: 1.7             | −0.80 IQR: 1.1          | 0.474   |
| Hip        | 0.19 ± 1.14                | 0.06 ± 0.99             | 0.275   |

IQR = Interquartile range

Table 3: Characteristics of asthmatic patients with normal and abnormal BMD

| Normal | Osteopenia/ Osteoporosis | P value |
|--------|--------------------------|---------|
| Male: Female | 10:65 | 10:58 | 0.813 |
| Ever smoker: Never smoker | 2:73 | 3:65 | 0.57 |
| Alcoholic: Non-alcoholic | 3:72 | 3:65 | 0.902 |
| Family history of osteoporosis | Yes: No | 6:72 | 0.902 |

BMD = Bone mineral density
of post-menopausal women, respectively, compared with only 1.6% and 33.3% of pre-menopausal women, respectively ($P=0.006$).

We subjected the age and BMI of the study patients to binary logistic regression (the outcome being either normal BMD or osteoporosis/osteopenia) and found that older patients were more likely to have osteoporosis/osteopenia of the spine (odds ratio [OR]=1.04, confidence interval [CI] 1.01-1.08), femur (OR=1.05, CI=1.01-1.09), and hip (OR=1.06, CI=1.01-1.12) and patients with higher BMIs were less likely to have osteoporosis/osteopenia of the spine (OR=0.94, CI=0.88-1.01), femur (OR=0.88, CI=0.82-0.96), and hip (OR=0.77, CI=0.66-0.89).

Among asthmatic patients, duration of asthma, asthma control, cumulative budesonide-years, and rescue oral prednisolone did not affect risks of osteopenia and osteoporosis [Table 5].

**Discussion**

Decreased BMD appeared to be largely under detected, even among our control subjects. A high percentage of control subjects were found to have osteoporosis/osteopenia, which would have otherwise gone undetected if not for their participation in this study. Similarly, it was through the National Osteoporosis Risk Assessment in the US that of 200,160 postmenopausal women (which included 1912 Asians), 39.6% were found to have osteoporosis and 7% with osteoporosis.[13] A study conducted in Malaysia reported a prevalence of osteoporosis of 24.1% in 514 disease-free, uterus-intact non-hormone replacement therapy-using women.[13]

For any meaningful analysis of the effects of ICS on BMD, a detailed evaluation of the baseline characteristics of the asthmatic group and the control group was essential to reduce bias during analysis. Although the number of female patients in our control group was higher than in the asthmatic group [Table 1], the difference in male to female ratio was not statistically significant between the two groups. All other characteristics were also matched between the two groups except for PAI, which was higher in the control group. One would expect a higher BMD among subjects who are more physically active, but this increase in the level of activity did not result in a significant difference in the T-scores of the control subjects compared with the asthmatic patients. The PAI value depended largely on the accuracy of the patient’s historical recall of physical activities conducted in an “average day.” Furthermore, the larger PAI IQR in the asthmatic patients suggests that the values obtained skewed toward the extremes. Although gender, genetic background (i.e., family history), cigarette smoking, alcohol consumption, and menopausal status are believed to be among the important factors influencing BMD,[14] our results suggested that these factors did not significantly affect the BMD of our study subjects. However, the number of patients recruited into our study who actually had a history of ever-smoking, alcohol consumption, or a family history of osteoporosis was small.

Not surprisingly, the older asthmatic patients in this study had lower BMD compared with younger patients, while patients with higher BMI had higher BMD compared to patients with lower BMI. This observation has also been reported by other studies such as the one conducted by Burger et al.[15] who reported that the BMD yearly rate of change increased and decreased with advancing age and BMI, respectively.

The results of our study suggest that the duration of asthma,

**Table 4: Correlation of T score of spine, femur and hip with age, BMI, and PAI**

|                  | T-score spine          | T-score femur          | T-score hip          |
|------------------|------------------------|------------------------|----------------------|
|                  | R  | P value | R  | P value | r  | P value |
| Age              | −0.230 | 0.006   | −0.287 | 0.001   | −0.328 | <0.001  |
| BMI              | 0.194  | 0.02    | 0.383  | <0.001  | 0.536  | <0.001  |
| PAI              | −0.039  | 0.646   | 0.043  | 0.613   | 0.026  | 0.757   |

BMI = Body mass index; PAI = Physical activity index

**Table 5: Asthma control, cumulative budesonide-years, rescue oral prednisolone, and duration of asthma in patients with normal BMD and patients with osteopenia/osteoporosis**

| Asthma control                  | Bone mineral density | $P$ value |
|---------------------------------|----------------------|-----------|
| N=39 (%)                        | Osteopenia/osteoporosis N=30 (%) |
| Controlled                      | 16 (41.0)            | 14 (46.7) | 0.896 |
| Partly controlled               | 10 (25.6)            | 7 (23.3)  |       |
| Uncontrolled                    | 13 (33.4)            | 9 (30.0)  |       |
| Cumulative budesonide-years (µg·year) |
| Less than 5 000                 | 25 (64.1)            | 22 (73.3) | 0.715 |
| 5 000 to less than 10 000       | 9 (23.1)             | 5 (16.7)  |       |
| 10 000 or more                  | 5 (12.8)             | 3 (10.0)  |       |
| Rescue oral steroid for past one year |
| None                            | 30 (76.9)            | 20 (66.7) | 0.344 |
| One or more                     | 9 (23.1)             | 10 (33.3) |       |
| Duration of asthma              |                      |           |       |
| 10 years or Less                | 12 (30.8)            | 10 (33.3) | 0.651 |
| 10-20 years                     | 13 (33.3)            | 7 (23.3)  |       |
| More than 20 years              | 14 (36.9)            | 13 (43.4) |       |

Asthma control: Uncontrolled, Controlled, Partly controlled; PAI: None, 10,000 or more; rescue oral prednisolone: None, 10,000 or more; duration of asthma: 10 years or Less, 10-20 years, More than 20 years; (BMD) Bone mineral density
asthma control, cumulative budesonide dose-years, and rescue oral prednisolone did not significantly affect the risk of osteopenia and osteoporosis among patients with bronchial asthma. The cumulative budesonide-years used in our study is the product of the mean daily equipotent dose of inhaled budesonide and the number of years on ICS; representative of the cumulative dose of ICS described in other studies, such as the one conducted by Toogood et al.\[11\]

Although several studies have shown that ICS either decrease or did not significantly affect BMD,\[6,10,16-18\] the study of 69 patients reported by Toogood et al.\[11\] showed a higher lumbar BMD Z-score in patients with a greater cumulative lifetime exposure to ICS (median >3 g) and a reduction in the number of patients at risk of fracture. We also found that the majority of our asthmatic patients (62.5%) who had higher cumulative ICS dose (more than 10 000 μg-years of cumulative budesonide-years) have normal BMD, although this was not statistically significant. We postulate that a higher dose of ICS given to asthmatic patients could have resulted in better asthma control which will then lead to an increase in physical activities and improved BMD.

In a large retrospective cohort study which included more than 100 000 patients in each arm, van Staa et al.\[9\] analyzed fracture risk among ICS users, inhaled bronchodilator users, and control subjects. The relative rates of non-vertebral, hip, and femur fractures among ICS users were higher than the control group, but not significantly different compared with the bronchodilator group. The authors concluded that ICS users had a higher risk of fracture, but this increased risk may be related to the underlying respiratory illness. They also found that the rate of fracture declined when treatment with ICS was discontinued.

Boulet et al.\[8\] studied 37 asthmatic subjects who had been using 800 μg/day or greater of beclomethasone or budesonide for more than 18 months, matched to a control group and found no significant difference in BMD between the two groups. In a separate study,\[9\] 374 patients with mild asthma were randomized to receive inhaled budesonide, inhaled beclomethasone dipropionate, or non-corticosteroid treatment for two years, and the authors reported that there was no difference in the change of BMD between the three groups. It is worthwhile to note that the median daily doses of inhaled budesonide and beclomethasone were 389 μg and 499 μg, respectively, which one can argue were in the lower range of ICS dosages used to treat bronchial asthma and are unlikely to have any significant effect on BMD. To study the effect of high-dose ICS on BMD, Hughes et al.\[10\] recruited 59 patients with moderate-to-severe asthma and randomized them to receive inhaled fluticasone propionate 500 μg twice daily and inhaled budesonide 800 μg twice daily for one year. They, too, concluded that treatment with high doses of either inhaled fluticasone propionate or budesonide during the one year of treatment did not demonstrate any significant difference in BMD. The short one-year duration of study may not be sufficient to observe any effect that ICS may have on BMD.

Prolonged use of oral steroids leads to BMD deterioration and ultimately an increased risk of fracture, a fact not many clinicians will dispute. We attempted to include the usage of oral steroids as rescue therapy in our study to evaluate the effect of oral steroids on BMD in our study population. As expected, more patients who received one or more courses of rescue oral steroids in the preceding year had osteopenia or osteoporosis compared with those who did not, but the difference was not statistically significant. The small number of subjects in this sub-group analysis probably explained the lack of statistical significance. Furthermore, the one-year duration may be too short to demonstrate any effect of intermittent courses of oral steroids on BMD.

In conclusion, asthmatic patients on ICS had no added risk of osteoporosis or osteopenia. Risk factors for osteoporosis and osteopenia among asthmatic patients are older age and lower BMI but not the cumulative dose of ICS.

The major limitation of our study was the dependence on historical recall in the process of data gathering.

References

1. Rugayah B. Public Health Institute, Ministry of Health Malaysia. Asthma. Report on Second National Health and Morbidity Survey 1997;11:94-8.
2. Malaysian Ministry of Health. Clinical Practice Guidelines for Management of Adult Asthma Revised 2002.
3. Global Initiative for Asthma. GINA report, Global Strategy for Asthma Management and Prevention 2006. Available from: http://www.ginasthma.org/ [Last Accessed on 2008 July 12].
4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:495-503.
5. Malaysian Osteoporosis Society. Clinical Practice Guidelines on Management of Osteoporosis 2006.
6. Boulet LP, Giugure MC, Milot J, Brown J. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994;94:796-803.
7. Hanania NA, Chapman KR, Sturtridge WC, Szlaij JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-9.
8. Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J 1999;13:1267-75.
9. Tattersfield AE, Town GI, Johnell O, Picado C, Aubier M, Braillon P, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001;56:272-8.
10. Hughes JA, Conry BG, Male SM, Eastell R. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax 1999;54:223-9.
11. Toogood JH, Baskerville JC, Markov AE, Hodson AB, Fraher LJ, Jennings B, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
12. Dawber TR. The Framingham study: The epidemiology of atherosclerotic disease. Cambridge (MA): Harvard University Press; 1980.
13. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001;286:2815-22.
14. Lim PS, Ong FB, Adeeb N, Seri SS, Noor-Aini MY, Shamsuddin K, et al. Bone health in urban midlife Malaysian women: Risk factors
and prevention. Osteoporosis Int 2005;16:2069-79.
15. Burger H, de Laet CE, van Daele PL, Weel AE, Witteman JC, Hofman A, et al. The Rotterdam study: Risk factors for increased bone loss in an elderly population. Am J Epidemiol 1998;147:871-9.
16. Goldstein MF, Joseph JF, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999;116:1733-49.
17. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
18. Ledford D, Apter A, Bronner AM, Rubin K, Prestwood K, Frieri M, et al. Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol 1998;102:353-62.
19. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581-8.
20. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.

How to cite this article: Kuan YC, How SH, Azian AA, Liam CK, Ng TH, Fauzi AR. Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country. Ann Thorac Med 2012;7:69-73.

Source of Support: Nil, Conflict of Interest: None declared.

New features on the journal's website

Optimized content for mobile and hand-held devices
HTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed.
Click on [Mobile Full text] from Table of Contents page.
This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

E-Pub for hand-held devices
EPUB is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device.
Click on [EPub] from Table of Contents page.
There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

E-Book for desktop
One can also see the entire issue as printed here in a ‘flip book’ version on desktops.
Links are available from Current Issue as well as Archives pages.
Click on [View as eBook]